UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 2164-8
Program Prior Authorization/Medical Necessity
Medication Inbrija® (levodopa inhalation powder)
P&T Approval Date 5/2019, 7/2019, 7/2020, 12/2020, 2/2022, 2/2023, 2/2024, 2/2025
Effective Date 5/1/2025
1. Background:
Inbrija® (levodopa inhalation powder) is an aromatic amino acid indicated for the intermittent
treatment of OFF episodes in patients with Parkinson’s disease treated with
carbidopa/levodopa.
Inbrija should only be administered with the Inbrija inhaler.
Coverage will be provided for members who meet the following criteria.
2. Coverage Criteriaa:
A. Initial Authorization
1. Inbrija will be approved based on all of the following criteria:
a. Diagnosis of Parkinson’s disease
-AND-
b. Inbrija will be used as intermittent treatment for OFF episodes1
-AND-
c. Prescribed by or in consultation with a neurologist or specialist in the treatment of
Parkinson’s disease
-AND-
d. Patient is currently on a stable dose of a carbidopa/levodopa-containing medication and
will continue receiving treatment with a carbidopa/levodopa-containing medication while
on therapy
-AND-
e. Patient continues to experience ≥ 2 hours of OFF time per day despite optimal
management of carbidopa-levodopa therapy including both of the following:
(1) Taking carbidopa/levodopa on an empty stomach or at least one half-hour or more
before or one hour after a meal or avoidance of high protein diet
© 2025 UnitedHealthcare Services, Inc.
1
-AND-
(2) Dose and dosing interval optimization
-AND-
f. History of failure, contraindication, or intolerance to two anti-Parkinson’s disease
therapy from the following adjunctive pharmacotherapy classes (trial must be from two
different classes):
(1) Dopamine agonists (e.g., pramipexole, ropinirole)
(2) Catechol-O-methyl transferase (COMT) inhibitors (e.g., entacapone)
(3) Monoamine oxidase (MAO) B inhibitors (e.g., rasagiline, selegiline)
Authorization will be issued for 12 months.
B. Reauthorization
1. Inbrija will be approved based on the following criterion:
a. Documentation of positive clinical response to Inbrija therapy
-AND-
b. Patient will continue to receive treatment with a carbidopa/levodopa-containing
medication
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-
10) and/or claim logic. Use of automated approval and re-approval processes varies by
program and/or therapeutic class.
• Supply limits and/or Step Therapy may be in place.
4. References:
1. Inbrija [package insert]. Pearl River, NY: Acorda Therapeutics, Inc.; December 2022.
2. LeWitt P, Hauser R, Pahwa R et al. Safety and efficacy of CVT-301 (levodopa inhalation
powder) on motor function during off periods in patients with Parkinson's disease: a
randomised, double-blind, placebo-controlled phase 3 trial. The Lancet Neurology.
2019;18(2):145-154.
© 2025 UnitedHealthcare Services, Inc.
2
3. Tarsy D. UpToDate. Medical management of motor Fluctuations and Dyskinesia in
Parkinson Disease. 2024 Sep. 23. Accessed December 20, 2024.
Program Prior Authorization/Medical Necessity - Inbrija® (levodopa inhalation
powder)
Change Control
5/2019 New program
7/2019 Updated clinical coverage criteria regarding prior anti-Parkinson’s
therapies.
7/2020 Annual review. No changes to coverage criteria.
12/2020 Removed evaluation of underlying lung disease from review criteria.
Updated references.
2/2022 Annual review with no change in clinical criteria.
2/2023 Annual review with no change in clinical criteria. Updated references.
2/2024 Annual review. Revised initial authorization to 12 months. Updated
references.
2/2025 Annual review with no change in clinical criteria. Updated references.
© 2025 UnitedHealthcare Services, Inc.
3